Geller Advisors LLC Makes New $216,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Geller Advisors LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,582 shares of the biopharmaceutical company’s stock, valued at approximately $216,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Avior Wealth Management LLC boosted its position in shares of Gilead Sciences by 1.2% during the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 108 shares in the last quarter. Concord Asset Management LLC VA lifted its stake in Gilead Sciences by 3.8% during the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 111 shares in the last quarter. TFB Advisors LLC lifted its stake in Gilead Sciences by 1.2% during the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after buying an additional 116 shares in the last quarter. Sumitomo Life Insurance Co. lifted its stake in Gilead Sciences by 0.7% during the third quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock valued at $1,494,000 after buying an additional 117 shares in the last quarter. Finally, FDx Advisors Inc. lifted its stake in Gilead Sciences by 2.2% during the third quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 117 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of a number of analyst reports. UBS Group upped their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Oppenheimer upped their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. BMO Capital Markets increased their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Royal Bank of Canada increased their price target on shares of Gilead Sciences from $81.00 to $84.00 and gave the stock a “sector perform” rating in a research report on Monday, November 18th. Finally, The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Twelve equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $95.41.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This trade represents a 1.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 476,591 shares of company stock worth $43,747,615. Insiders own 0.29% of the company’s stock.

Gilead Sciences Trading Down 1.7 %

Shares of GILD stock opened at $90.59 on Tuesday. The business’s 50 day moving average is $89.33 and its two-hundred day moving average is $78.89. The company has a market cap of $112.90 billion, a PE ratio of 1,006.56, a price-to-earnings-growth ratio of 2.86 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company posted $2.29 earnings per share. Equities analysts predict that Gilead Sciences, Inc. will post 4.37 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a $0.77 dividend. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.40%. Gilead Sciences’s payout ratio is 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.